Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levitra · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Levitra (Vardenafil, BAY38-9456) | DRUG | 4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks |
Inclusion Criteria: * Males with ED according to the NIH definition (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance) for at least 3 months. * Heterosexual relationship * Age range: 18 years and older * Documented written Informed Consent * The su...
Levitra is used for erectile dysfunction. It is a small molecule being developed by Amgen Inc. (AMGN) for this condition. The drug is currently in Phase 3 clinical development.
Levitra is being developed by Amgen Inc., which trades under the ticker AMGN. The drug is in Phase 3 clinical development for erectile dysfunction.
Levitra is in Phase 3 clinical development. It is an investigational drug for erectile dysfunction and has not been approved by the FDA.
Levitra has one completed Phase 3 trial, NCT00657644, titled 'Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.' This trial enrolled 130 male participants aged 18 years and older in Russia.
Levitra is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for erectile dysfunction, with one completed clinical trial.